Abstract
No public abstract is available from the verified source records.
Guoxing Zhu, Nanyi Zheng, Pengfei Zhai
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global incidence and mortality of severe fungal disease
10.1016/s1473-3099(23)00692-8 · 2024
Editorial: the World Health Organization (WHO) fungal priority pathogens list in response to emerging fungal pathogens during the COVID-19 pandemic
10.12659/msm.939088 · 2022
COVID-19-associated fungal infections: An urgent need for alternative therapeutic approach?
10.3389/fmicb.2022.919501 · 2022
Climate change: Shifting boundaries of fungal disease in Europe and beyond
10.1136/thorax-2024-222168 · 2025
Interconnected worlds: A comprehensive review of fungal defenses, antimicrobial resistance, and their evolutionary dynamics
10.3897/imafungus.17.171995 · 2026
Differentiation of Pneumocystis jirovecii pneumonia from colonization: A clinical decision framework incorporating risk stratification and next-generation sequencing thresholds
10.1186/s12879-025-11235-4 · 2025
Novel model to predict risk of invasive fungal infection and fungal prophylaxis timing
10.1128/spectrum.02958-24 · 2025
Fungal drug response and antimicrobial resistance
10.3390/jof9050565 · 2023
The Lancet Infectious Diseases: An exciting time for antifungal therapy
10.1016/s1473-3099(23)00380-8 · 2023
Antifungal pipeline
10.3389/fcimb.2021.732223 · 2021
Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections
10.2165/00003495-200969030-00010 · 2009
Fungal lanosterol 14α-demethylase: A target for next-generation antifungal design
10.1016/j.bbapap.2019.02.008 · 2020
Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata
10.3390/jof4030105 · 2018
Resistance of Candida to azoles and echinocandins worldwide
10.1016/j.cmi.2019.03.028 · 2019
5-flucytosine longitudinal antifungal susceptibility testing of Cryptococcus neoformans: A substudy of the EnACT trial testing oral amphotericin
10.1093/ofid/ofad596 · 2023
Emerging drugs and vaccines for candidemia
10.1111/myc.12265 · 2014
Candida auris genetics and emergence
10.1146/annurev-micro-032521-015858 · 2023
Unresolved referenced work
Kept as external metadata until matched
New antifungal strategies and drug development against WHO critical priority fungal pathogens
10.3389/fcimb.2025.1662442 · 2025
The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin
10.1007/s40265-021-01611-0 · 2021
Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019)
10.1016/j.jgar.2021.04.012 · 2021
Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis
10.1128/aac.00366-11 · 2011
Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents
10.3390/jof8080857 · 2022
Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers
10.1128/aac.01623-22 · 2023
Fosmanogepix for the treatment of invasive mold diseases caused by Aspergillus species and rare molds: A phase 2, open-label study (AEGIS)
10.1093/cid/ciaf185 · 2025
Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly
10.1046/j.1365-2958.2003.03481.x · 2003
GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast
10.1074/jbc.m301044200 · 2003
E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis
10.1128/aac.00731-11 · 2012
In vitro activity of APX2041, a new Gwt1 inhibitor, and in vivo efficacy of the prodrug APX2104 against Aspergillus fumigatus
10.1128/aac.00682-21 · 2021
Chemical genomics-based antifungal drug discovery: Targeting glycosylphosphatidylinositol (GPI) precursor biosynthesis
10.1021/id5000212 · 2015
Calcineurin inhibitors synergize with manogepix to kill diverse human fungal pathogens
10.3390/jof8101102 · 2022
New perspectives on antimicrobial agents: Fosmanogepix
10.1128/aac.00324-26 · 2026
Rho2-dependent cell wall remodeling boosts the fungistatic activity of manogepix against Aspergillus fumigatus
10.1016/j.tcsw.2025.100166 · 2025
The wound microbiota: Microbial mechanisms of impaired wound healing and infection
10.1038/s41579-024-01035-z · 2024
Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains
10.1128/aac.00137-25 · 2025
Evaluation of resistance development to the Gwt1 inhibitor manogepix (APX001A) in Candida species
10.1128/aac.01387-19 · 2019
Structural insights into the inhibition mechanism of fungal GWT1 by manogepix
10.1038/s41467-024-53512-x · 2024
Enhanced efflux pump expression in Candida mutants results in decreased manogepix susceptibility
10.1128/aac.00261-20 · 2020
TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression
10.1128/aac.01508-24 · 2025
Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in Candida auris (Candidozyma auris), Candida albicans, Candida parapsilosis, and Candida glabrata (Nakaseomyces glabratus)
10.1128/aac.00680-25 · 2025
Galactomannan is a biomarker of Fosmanogepix (APX001) efficacy in treating experimental invasive pulmonary Aspergillosis
10.1128/aac.01966-19 · doi-reference
APX001 pharmacokinetic/pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary Aspergillosis
10.1128/aac.02372-18 · doi-reference
Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin- and multidrug resistant Candida isolates in a mouse model of invasive Candidiasis
10.1128/aac.00425-18 · doi-reference
In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated Candidiasis mouse model
10.1128/aac.02542-17 · doi-reference
In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods
10.1128/aac.00570-11 · doi-reference
Aminopyrifen, a novel 2-aminonicotinate fungicide with a unique effect and broad-spectrum activity against plant pathogenic fungi
10.1584/jpestics.d20-094 · doi-reference
Antifungal chemotherapies and immunotherapies for the future
10.1111/pim.12960 · doi-reference
Antifungal agents in the 21st century: advances, challenges, and future perspectives
10.3390/idr17040091 · doi-reference
Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of Candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits
10.1128/aac.01795-20 · doi-reference
Novel approaches in the management of mucormycosis
10.1007/s12281-023-00463-3 · doi-reference
The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo
10.1093/mmy/myad118 · doi-reference
Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro
10.1128/aac.01645-22 · doi-reference
The importance of antimicrobial resistance in medical mycology
10.1038/s41467-022-32249-5 · doi-reference
Fosmanogepix treatment for coccidioidomycosis under an expanded access program
10.1093/cid/ciag271 · doi-reference
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: Results from a phase 2 trial
10.1093/jac/dkad256 · doi-reference
Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: Results from a phase 2 trial
10.1128/aac.01419-22 · doi-reference
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia
10.1093/jac/dkad269 · doi-reference
The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections
10.1128/aac.00380-22 · doi-reference
Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis
10.1128/aac.01735-19 · doi-reference
APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia
10.1128/aac.01715-18 · doi-reference
APX001 is effective in the treatment of murine invasive pulmonary aspergillosis
10.1128/aac.01713-18 · doi-reference
Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis
10.1128/aac.01120-19 · doi-reference
In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris
10.1128/aac.02319-17 · doi-reference
Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus
10.1128/aac.00178-20 · doi-reference
Manogepix, the active moiety of the investigational agent fosmanogepix, demonstrates in vitro activity against members of the Fusarium oxysporum and Fusarium solani species complexes
10.1128/aac.02343-20 · doi-reference
Environmental hot spots and resistance-associated application practices for azole-resistant Aspergillus fumigatus, Denmark, 2020-2023
10.3201/eid3008.240096 · doi-reference
In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination
10.1128/aac.00730-20 · doi-reference
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019-24)
10.1093/jac/dkag016 · doi-reference
Activity of novel antifungal compound APX001A against a large collection of Candida auris
10.1093/jac/dky302 · doi-reference
Manogepix (APX001A) in vitro activity against Candida auris: Head-to-head comparison of EUCAST and CLSI MICs
10.1128/aac.00656-20 · doi-reference
In vitro activity of manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak
10.1128/aac.01124-20 · doi-reference
Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods
10.1128/aac.05414-11 · doi-reference
In vitro antifungal activity of manogepix and other antifungal agents against South African Candida auris isolates from bloodstream infections
10.1128/spectrum.01717-21 · doi-reference
In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies
10.1093/jac/dkz022 · doi-reference
In vitro and in vivo evaluation of APX001A/APX001 and other Gwt1 inhibitors against Cryptococcus
10.1128/aac.00523-18 · doi-reference
New treatment options for critically important WHO fungal priority pathogens
10.1016/j.cmi.2024.03.006 · doi-reference
In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022)
10.1128/aac.01132-23 · doi-reference
Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: Comparison of CLSI and European committee on antimicrobial susceptibility testing methods
10.1093/jac/dkr342 · doi-reference
In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds
10.1128/aac.00291-11 · doi-reference
The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans
10.1128/aac.03944-14 · doi-reference